USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS Russian patent published in 2022 - IPC C07K16/30 A61K39/395 A61P35/00 

Abstract RU 2771173 C2

FIELD: biotechnology.

SUBSTANCE: disclosed is a multimeric antibody which recognizes ganglioside OAcGD2 for the selective delivery of at least one anti-cancer agent having a molecular weight in range of 100 to 200,000 Da, into a cell expressing ganglioside OAcGD2. Said antibody is used in a composition and method for delivering an anti-cancer agent into a cell expressing ganglioside OAcGD2, in a method for increasing the effectiveness of treating cancer expressing ganglioside OAcGD2 using an anticancer agent, in methods for preventing and treating refractory or recurrent cancer in a patient.

EFFECT: invention provides a synergistic effect of a combined treatment with an antibody specifically targeting ganglioside OAcGD2, and anticancer agents on forms of cancer expressing ganglioside OAcGD2, which enables to reduce dosages and, consequently, toxic side effects from anticancer agents.

22 cl, 7 dwg, 6 tbl

Similar patents RU2771173C2

Title Year Author Number
IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN 2012
  • Morisso Sebastyan Danel
  • Teppa Zheraldin
  • Zhak Yannik Loran Zhozef
  • Rober Bruno Zhilber Mark
  • De Martinoff Gi Lyuk Mishel
  • Beshar David
RU2763298C2
TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES 2018
  • Guz, Elvire
  • Garsiya, Stefani
RU2794170C2
GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 2020
  • Rontsitti, Dzhuzeppe
  • Zhoz, Luiza
  • Sharl, Severin
  • Mingotstsi, Frederiko
RU2815545C2
CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR 2018
  • Barret Jean-Marc
  • Prost Jean-Francois
  • Lahmar Mehdi
  • Degove Stephane
  • Bougherara Houcine
  • Donnadieu Emmanuel
RU2805232C2
POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION 2017
  • Guz, Elvire
  • Garsiya, Stefani
RU2751483C2
COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT 2016
  • Yamada Taketo
  • Khayasi Mutsumi
  • Yamada Kokhdzi
  • Morimoto Tikao
  • Okamoto Tosikhiro
  • Kaneko Yutaro
RU2742953C2
STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE 2018
  • De, Arnab
  • Narasimkhan, Chakravarti Nachu
RU2820576C2
DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES 2014
  • Morsey, Mohamad
  • Zhang, Yuanzheng
  • Tarpey, Ian
RU2815059C2
PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 2017
  • Rotter, Varda
  • Oren, Moshe
  • Tal, Perry
  • Eizenberger, Shay
  • Ben-Shimon, Avi
RU2762089C2
DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES 2014
  • Morsey, Mohamad
  • Zhang, Yuanzheng
  • Tarpey, Ian
RU2801209C2

RU 2 771 173 C2

Authors

Birkl, Stefan

Flerans, Zhyulen

Farazh, Sebastyan

Le Dussal, Zhan-Mark

Koshonno, Deni

Term, Mikael

Assulin, Brizhitt

Dates

2022-04-28Published

2017-12-05Filed